Biggest News Aggregation in the World
📰 Stephens Yoder News

Stephens Yoder News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Stephens Yoder. Real-time updates on events, politics, business and more.

Pieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Reports Full-Year 2022 Financial Results and Business Updates

COMPANY TO HOST AN INVESTOR CONFERENCE CALL TODAY, WEDNESDAY, MARCH 29, 2023, AT 8:00 AM EDTContinued advancement of pipeline, including two clinical-stage inhaled respiratory programs and additional therapeutic
United States Stephens Yoder Exchange Commission Securities Exchange Company Quarterly Reports On Form Pieris Pharmaceuticals Inc View

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Pieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Announces $5 Million Milestone from Seagen for Initiation of Phase 1 Trial of CD228 x 4-1BB Bispecific Molecule

BOSTON, MA / ACCESSWIRE / January 10, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology
United States Stephens Yoder Society For Immunotherapy Of Cancer Pieris Pharmaceuticals Company Quarterly Reports On Form Company Annual Report On Form

Pieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON WEDNESDAY, NOVEMBER 2, 2022 AT 8:00 AM EDTElarekibep (PRS-060/AZD1402) phase 2a study for asthma enrollment continuesFirst subject dosed in PRS-220 phase
United States Stephens Yoder Maria Kelman Society For Immunotherapy Of Cancer Pieris Pharmaceuticals Boston Pharmaceuticals

Pieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON THURSDAY, AUGUST 4, 2022 AT 8:00 AM EDTAdjustments to PRS-060/AZD1402 phase 2 study design boost enrollment rate and facilitate a topline readout by 3Q23Cinrebafusp
United States Stephens Yoder Maria Kelman Pieris Pharmaceuticals Boston Pharmaceuticals Company Quarterly Reports On Form

Pieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

Company To Host an Investor Conference Call On Wednesday, May 11, 2022 At 8:00 Am EDTBOSTON, MA / ACCESSWIRE / May 11, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology
United States Stephens Yoder Maria Kelman Pieris Pharmaceuticals Boston Pharmaceuticals Company Quarterly Reports On Form

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science